A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
Inclusion Criteria:
- Eligible participants who completed Visit 7, and Visit 8 if applicable, of Study 3101-303-002 or Study 3101-304-002 without significant protocol deviations and who did not experience an Adverse Event that may indicate an unacceptable safety risk.
Exclusion Criteria:
Los Alamitos, California 90720-3500, United States
Newport Beach, California 92660, United States
Sherman Oaks, California 91403, United States
Fort Wayne, Indiana 46804, United States
Indianapolis, Indiana 46256, United States
Salt Lake City, Utah 84109, United States
Salt Lake City, Utah 84121, United States
St-Priest-en-Jarez, Pays de la Loire Region 42270, France
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-079, Poland
Lublin, Lublin Voivodeship 20-582, Poland
Busan, Busan Gwang Yeogsi 49241, South Korea
Taipei City, Taipei 11217, Taiwan